Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
VYGR Stock Overview
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies.
Voyager Therapeutics Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.76 |
52 Week High | US$10.60 |
52 Week Low | US$2.46 |
Beta | 1.1 |
1 Month Change | 0.17% |
3 Month Change | -38.98% |
1 Year Change | 32.41% |
3 Year Change | -78.84% |
5 Year Change | -35.71% |
Change since IPO | -67.55% |
Recent News & Updates
Looking Back In On Voyager Therapeutics
Today, we revisit Voyager Therapeutics for the first time in a year. The company has signed licensing deals with two large drug makers since we last looked in on it and net cash represents most of the stock's current market capitalization. A full investment analysis follows in the paragraphs below.
Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
The analysts covering Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) delivered a dose of negativity to shareholders today...
Shareholder Returns
VYGR | US Biotechs | US Market | |
---|---|---|---|
7D | 15.2% | 10.3% | 6.6% |
1Y | 32.4% | -24.3% | -18.4% |
Return vs Industry: VYGR exceeded the US Biotechs industry which returned -24.4% over the past year.
Return vs Market: VYGR exceeded the US Market which returned -18.5% over the past year.
Price Volatility
VYGR volatility | |
---|---|
VYGR Average Weekly Movement | 16.8% |
Biotechs Industry Average Movement | 13.2% |
Market Average Movement | 8.1% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VYGR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: VYGR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 101 | Al Sandrock | https://www.voyagertherapeutics.com |
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company’s lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson’s disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington’s disease; VY-FXN01 for Friedreich’s ataxia; and Tau program for the treatment of tauopathies, including Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.
Voyager Therapeutics Fundamentals Summary
VYGR fundamental statistics | |
---|---|
Market Cap | US$221.51m |
Earnings (TTM) | -US$70.87m |
Revenue (TTM) | US$31.57m |
7.0x
P/S Ratio-3.1x
P/E RatioIs VYGR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VYGR income statement (TTM) | |
---|---|
Revenue | US$31.57m |
Cost of Revenue | US$65.79m |
Gross Profit | -US$34.22m |
Other Expenses | US$36.65m |
Earnings | -US$70.87m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -1.84 |
Gross Margin | -108.38% |
Net Profit Margin | -224.46% |
Debt/Equity Ratio | 0% |
How did VYGR perform over the long term?
See historical performance and comparisonValuation
Is VYGR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VYGR?
Other financial metrics that can be useful for relative valuation.
What is VYGR's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$221.51m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.1x |
Enterprise Value/EBITDA | -1.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VYGR's PS Ratio compare to its peers?
VYGR PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1212.2x |
Price-To-Sales vs Peers: VYGR is good value based on its Price-To-Sales Ratio (7x) compared to the peer average (1212.2x).
Price to Earnings Ratio vs Industry
How does VYGR's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Sales vs Industry: VYGR is good value based on its Price-To-Sales Ratio (7x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is VYGR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 7x |
Fair PS Ratio | 0.7x |
Price-To-Sales vs Fair Ratio: VYGR is expensive based on its Price-To-Sales Ratio (7x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).
Share Price vs Fair Value
What is the Fair Price of VYGR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VYGR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VYGR's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VYGR's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Voyager Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-10.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VYGR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VYGR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VYGR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VYGR's revenue is expected to decline over the next 3 years (-8.8% per year).
High Growth Revenue: VYGR's revenue is forecast to decline over the next 3 years (-8.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VYGR is forecast to be unprofitable in 3 years.
Discover growth companies
Past Performance
How has Voyager Therapeutics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
17.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VYGR is currently unprofitable.
Growing Profit Margin: VYGR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VYGR is unprofitable, but has reduced losses over the past 5 years at a rate of 17.6% per year.
Accelerating Growth: Unable to compare VYGR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VYGR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: VYGR has a negative Return on Equity (-93.33%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Voyager Therapeutics's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: VYGR's short term assets ($170.7M) exceed its short term liabilities ($101.7M).
Long Term Liabilities: VYGR's short term assets ($170.7M) exceed its long term liabilities ($46.6M).
Debt to Equity History and Analysis
Debt Level: VYGR is debt free.
Reducing Debt: VYGR has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable VYGR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: VYGR is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 11.1% per year.
Discover healthy companies
Dividend
What is Voyager Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VYGR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VYGR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VYGR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VYGR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VYGR has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
Al Sandrock (63 yo)
0.25
Tenure
Dr. Alfred W. Sandrock Jr., also known as Al, M.D., Ph D., served as Director at Verge Analytics, Inc. since February 2022. He serves as Member of Scientific Advisory Board at Camp4 Therapeutics Corporatio...
Leadership Team
Experienced Management: VYGR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Experienced Board: VYGR's board of directors are considered experienced (5.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Voyager Therapeutics, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Voyager Therapeutics, Inc.
- Ticker: VYGR
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$221.507m
- Shares outstanding: 38.46m
- Website: https://www.voyagertherapeutics.com
Number of Employees
Location
- Voyager Therapeutics, Inc.
- 75 Sidney Street
- Cambridge
- Massachusetts
- 2139
- United States
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/26 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.